MONROVIA, Calif., April 23, 2014 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, today announced that it is hosting an investor breakfast and webcast on Saturday, April 26 during the ASCRS Symposium on cataract and refractive surgery in Boston, MA.
The meeting will feature presentations by two leading ophthalmologists who spoke at the recent FDA Ophthalmic Devices Panel meeting at which the STAAR Visian® Toric Implantable Collamer Lens (TICL) received a favorable vote on safety and effectiveness. Dr. Gregory D. Parkhurst, a cornea specialist at the Parkhurst Nuvision Clinic in San Antonio, and former Chief of Ophthalmology and Refractive Surgery at the world's largest military base will speak on how he has used the Visian ICL in his practice and in his military experience. Dr. Robert P. Rivera, Director of Clinical Research at the Hoopes Vision Center outside of Salt Lake City, will speak on the unmet need in the U.S. market for the TICL and how he plans to use it in his practice once available.
Robin Hughes, Vice President of Research and Development, will present on the new Preloaded ICL and the V6 projects utilizing the proven ICL platform with enhanced optical designs to treat and delay the onset of presbyopia. Barry G. Caldwell, President and CEO, will provide a brief update on the Company's operational progress, as well as highlights from the recent FDA Ophthalmic Devices Panel meeting.
Investors participating in ASCRS and interested in attending the breakfast meeting should contact Leigh Salvo at email@example.com or call (415) 568-9348. A live audio webcast of the presentation will be available at 4:30 a.m. PT/7:30 a.m. ET from the investor section of the Company's website at www.staar.com/html/investor-info.html. The webcast will also be archived and available for 90 days following the event.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL." A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL." More than 425,000 Visian ICLs have been implanted to date; to learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 335 full time employees and markets lenses in over 60 countries. Headquartered in Monrovia, CA, it manufactures in the following locations: Nidau, Switzerland; Aliso Viejo, CA; and Monrovia, CA. For more information, please visit the Company's website at www.staar.com.
Doug Sherk, 415-652-9100
Leigh Salvo, 415-568-9348
SOURCE STAAR Surgical Company